Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'AFFIRM: A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis'. The following are the other relevant details related to the trial:
Therapeutic Area: Hepatology
Trial Centre(s):
Changi General Hospital
National University Hospital
Singapore General Hospital
Tan Tock Seng Hospital
Trial Status: NA
Principal Investigator(s):
Dr Eugene Wong Yu Jun
Dr Mark Muthiah
Dr Rajneesh Kumar
Dr Yew Kuo Chao
Published by HT Digital Content Services with permission from Health Daily Digest....